Certain persons within the senior management have sold shares to enable financing of shares through Immunovia’s share option program

Lund (Sweden) - Hans Liljeborg, CFO and Lotta Blomgren, Operations Director, which are members of the senior management of Immunovia AB (publ) (“Immunovia” or the “Company”) have today sold shares in Immunovia to mainly enable the financing of shares through the Company’s share option program. Furthermore, Rolf Ehrnström, CSO, has sold shares in the same transaction and announced that it is for the purposes of acquiring a private property. The sale of the shares was carried out within the same transaction amounting to a total of 65,000 share at a price of SEK 145.0 per share. The buyer of the shares is a Swedish institutional investor.

The sale of the shares was distributed as follows:

  • Hans Liljenborg, 35,000 shares
  • Lotta Blomgren, 20,000 shares
  • Rolf Ehrnström, 10,000 shares

The sellers have, in relation to Vator Securities, committed to lock-up restrictions, which means that the sellers, with certain exceptions, are not allowed to sell shares in the Company for 180 days from today's date. The main reasons for the sale from Hans Liljenborg and Lotta Blomgren is to finance the acquisition of shares that are subscribed through the share option programm issued to employees in Immunovia (Series 2016/2019) and settlement of capital gains tax. Hans Liljenborg and Lotta Blomgren have in total subscribed for 80,000 shares in the share option programme. Rolf Ehrström has announced that the sale concerns financing of a private property.

For more information, please contact:

Julie Silber, Director of Investor Relations, Immunovia

Email: julie.silber@immunovia.com

Tel: +46 7 93 486 277

About Immunovia 
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com)

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###

About Us

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.

Subscribe